Evaluation of cancer cryoablation therapy efficacy based on DNA methylation detection

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081924

Enrollment

Unknown

Registered

2024-03-15

Start date

2024-03-15

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer and liver cancer

Interventions

Observers (Cryoablation therapy):None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18 and above; (2) Tumor patients who require cryoablation therapy after clinical evaluation (liver cancer/lung cancer, clinical stage = stage II); (3) Be able to understand the purpose of this study, sign an informed consent form, and be willing to cooperate with blood collection operations during the diagnosis and treatment process; (4) Willing to cooperate with the follow-up of this study and have MRI/CT test results before and after cryoablation therapy;

Exclusion criteria

Exclusion criteria: (1) Not willing to sign an informed consent form; (2) Patients with other malignant tumors simultaneously;

Design outcomes

Primary

Measure	Time frame
Plasma free tumor DNA methylation;RECIST1.1 ;Overall Survival;rogression-free survival;	—

Countries

China

Contacts

Public ContactLizhi Niu

Guangzhou Fuda Cancer hospital

niuboshi@fudahospital.com+86 189 2892 2088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026